Glucosamine: Forms, Arthritis Evidence and Safety

What is glucosamine?

Glucosamine is an amino sugar the body makes and uses to build cartilage, the cushioning tissue in joints.

Many glucosamine supplements are made from shellfish shells.

There is no recognized glucosamine deficiency or test that shows a person needs a supplement; the body makes the glucosamine it uses.

Glucosamine is sold as glucosamine hydrochloride or glucosamine sulfate, usually 1,500 mg a day, often combined with chondroitin (another cartilage component), MSM (methylsulfonylmethane, a sulfur compound), or other ingredients.

People take glucosamine for joint pain from osteoarthritis, the wear-and-tear arthritis of the knees, hips, and hands. Trial results conflict: the large US trial found no clear overall pain benefit over placebo, some sulfate trials were positive, and professional guidelines differ.

What glucosamine does in your body

The body makes glucosamine-containing compounds used to build larger molecules in cartilage and other tissues. Some of these form long carbohydrate chains that help hold water within the material surrounding cells. In a joint, that water-rich structure contributes to cartilage's ability to withstand compression.

Cartilage is maintained by living cells that continually make and break down its components. Providing a starting ingredient is therefore only one part of a much more complex process involving cell activity, loading and tissue damage.

A swallowed glucosamine tablet is digested and absorbed before any material reaches a joint. Cartilage-rebuilding claims require clinical evidence. ^[1]

What people take glucosamine for

The trials included people with differing levels of knee pain. A more favorable result for the combination of glucosamine and chondroitin in a smaller moderate-to-severe-pain group was not the large trial's main question. The cited trials have not established which people, if any, are more likely to benefit. The National Center for Complementary and Integrative Health calls the overall benefit uncertain.

When to ask a doctor before taking glucosamine

• You take warfarin (a blood thinner). Glucosamine with or without chondroitin has been linked to a higher bleeding risk in people taking warfarin. If you take a different blood thinner, ask the prescriber or pharmacist whether that evidence changes the advice for your medicine.
• You have diabetes or high blood sugar. Glucosamine may raise blood sugar in some people.
• You are allergic to shellfish. Many products are made from shellfish shells and say so on the label.
• You are pregnant or breastfeeding. Studies have not established whether glucosamine or chondroitin supplements are safe during pregnancy or while breastfeeding, according to NCCIH^[1].

What you can buy

Glucosamine comes as hydrochloride tablets, sulfate capsules, and multi-ingredient combinations. The table compares four common listing types with the preparations used in the main trials.

What to pay attention to on the label

The number to find is milligrams of glucosamine and which salt it is, plus the amount of every other ingredient.

Which number on the label is the amount?

Read the line that names glucosamine and its form (HCl or sulfate) in milligrams per serving. One tablet lists 1,500 mg of glucosamine hydrochloride (HCl), once a day, plus vitamin D and boswellia. One combination product lists 1,500 mg of glucosamine HCl and 1,200 mg of chondroitin per two tablets, the same amounts as the combination-treatment group in the US trial.

Misleading labels

Salt weight and extra minerals

One sulfate product lists 1,500 mg of glucosamine sulfate per three capsules, supplied by 2,000 mg of a potassium glucosamine sulfate complex, and separately declares 260 mg of potassium. These are different label declarations, not numbers to add or subtract: use the 1,500 mg line when comparing glucosamine sulfate, and count the 260 mg if you limit potassium. The label does not break down the remaining mass of the 2,000 mg complex.

Proprietary blends that hide amounts

One "double strength" product lists 1,500 mg of glucosamine HCl and a 1,288 mg blend of chondroitin, MSM, collagen, boswellia, and hyaluronic acid, with no amount for each.

Confusing servings and items per serving

Some manufacturers put 180 capsules on the front, and the back says 3 capsules per serving and 60 servings. The amount on the Supplement Facts panel is for the whole 3-capsule serving.

Match a product claim to the preparation studied

The labels in the table show why a claim about glucosamine cannot be checked by dose alone. A 1,500 mg hydrochloride tablet matches the amount in the positive European trial but not its sulfate preparation. The sulfate capsules use a different formulation from the registered medicine in that trial. The hydrochloride-plus-chondroitin combination matches the amounts tested in the large US trial, which found no clear overall pain benefit. We did not verify a specific manufacturer's advertising claim that cites the European result for one of these different retail products.

Common Myths about Glucosamine

Does glucosamine work for knee or hip arthritis?

For knee arthritis, results are mixed. In the 2006 US trial, 60 percent of people on placebo had at least a 20 percent drop in knee pain over 24 weeks. Glucosamine hydrochloride added about 4 percentage points, chondroitin about 5, and their combination about 7; none of those differences was statistically clear. The anti-inflammatory drug celecoxib added 10 points and did beat placebo. In the smaller moderate-to-severe-pain group, the combination reached that pain response more often than placebo (79 versus 54 percent).

Some crystalline-sulfate trials found modest symptom improvements, while a later sulfate trial found no pain advantage over placebo. These knee studies do not establish benefit for hip arthritis. The science section separates the preparations and explains the disagreement.

Is glucosamine sulfate better than glucosamine hydrochloride?

It has not been shown. Positive trials used a specific crystalline glucosamine sulfate preparation; the US GAIT trial used hydrochloride. Those trials also differed in participants, duration, funding and outcomes. None of the efficacy trials discussed here directly randomized the two salts against each other, so they cannot establish that the salt caused the difference.

Does glucosamine rebuild cartilage?

Glucosamine has not been shown to regrow cartilage. Some three-year sulfate trials found less narrowing of the space between knee bones on X-rays. That measurement is used to track structural progression, but it does not directly show newly grown cartilage. Other trials found no clear single-ingredient structural benefit, and changes in joint space did not consistently bring pain relief.

Drawbacks and side effects

Understanding these risks

There is no official upper limit for glucosamine, and no trial here tested amounts above 1,500 mg a day. In the European trial, safety and dropouts were similar on glucosamine and placebo.

NIH LiverTox^[2] lists uncommon, usually mild abdominal discomfort, nausea, tiredness and headache. Overall side effects in placebo-controlled trials were no more frequent with glucosamine, so these symptoms were not clearly more common than with placebo.

The two-year GAIT follow-up^[3] recorded 84 serious adverse events in 64 participants across its five treatment groups. Five events were considered possibly treatment-related: a heart attack in the glucosamine–chondroitin group, coronary angioplasty in the placebo group, and three events in the celecoxib group. In the separate LEGS trial^[4], 34 of 605 participants (6%) reported possibly related adverse events; the abstract does not break those down by treatment.

The science behind glucosamine

The main distinction is between relief of pain and changes on X-rays. They are separate outcomes, and trials have tested different glucosamine preparations. The US GAIT trial was funded by the National Institutes of Health but also received donated drugs; several authors disclosed pharmaceutical-company relationships.

The US trial and follow-ups did not find clear overall benefits

GAIT^[5] assigned 1,583 adults with knee osteoarthritis to glucosamine hydrochloride 1,500 mg/day, chondroitin sulfate 1,200 mg/day, both, celecoxib 200 mg/day or placebo for 24 weeks. Glucosamine was given as 500 mg three times daily. Its main pain result is described above.

The two-year structural follow-up^[6] had 572 eligible participants, but the X-ray analysis included 357 people and 581 knees, spread across the five treatments. Only 77 analyzed people received glucosamine alone. After adjustment, joint-space loss was 0.013 mm with hydrochloride and 0.166 mm with placebo. The difference favored glucosamine by 0.153 mm, but the 95% confidence interval—the range of effects compatible with the data under the analysis—ran from 0.379 mm less loss to 0.074 mm more loss.

A separate symptom report from the same GAIT follow-up^[3] followed a 662-person cohort. Neither hydrochloride nor the combination showed a clear advantage in the chance of achieving a 20 percent pain reduction over two years. The glucosamine result was compatible with either a lower or a higher chance of pain relief than placebo.

Sulfate trials found both favorable and null results

The 2001 European trial^[7] assigned 212 people with knee osteoarthritis to glucosamine sulfate 1,500 mg/day or placebo for three years. Mean joint-space loss was 0.06 mm with sulfate and 0.31 mm with placebo; symptoms also favored sulfate.

A second three-year trial, published in 2002^[8], tested crystalline glucosamine sulfate 1,500 mg once daily against placebo in 202 adults with knee osteoarthritis. The analysis including all randomized participants favored sulfate by 0.23 mm in joint-space change (95% confidence interval 0.09–0.37 mm). On the WOMAC symptom questionnaire, pain improved by 0.7 points more than placebo (95% confidence interval 0.06–1.3), and physical-function scores also favored sulfate. The paper describes a 25-point pain scale, so the average pain difference was small. Only 66 of 101 sulfate recipients and 55 of 101 placebo recipients completed three years; the analysis filled in missing final results using assumptions. The manufacturer funded the study, and people with a body mass index above 27 or clinically evident diabetes were excluded.

The later LEGS trial^[9] assigned 605 adults with chronic knee pain and X-ray evidence of osteoarthritis to glucosamine sulfate 1,500 mg/day, chondroitin sulfate 800 mg/day, both, or placebo. After two years, the combination had 0.10 mm less joint-space narrowing than placebo (95% confidence interval 0.002–0.20 mm); neither ingredient alone showed a statistically clear structural effect. Pain improved in all four groups during the first year, without a clear difference between treatments. Its small imaging advantage for the combination therefore came without a demonstrated pain advantage.

The pooled pain result prompted a published disagreement

The 2010 review combining trial results^[10] included 10 large trials and 3,803 participants across glucosamine, chondroitin and combination comparisons. It estimated that glucosamine reduced pain by 0.4 cm more than placebo on a 10 cm scale; the model's 95% uncertainty range was 0.1–0.7 cm. That was below the reviewers' chosen 0.9 cm threshold for a clinically important difference. Effects were smaller in industry-independent trials.

In published letters and the authors' reply^[11], critics argued that the threshold was too demanding and that pooling prescription sulfate with other preparations obscured benefits. The reviewers defended their threshold and analyses and retained their conclusion. Several critics disclosed relevant company funding or employment. The exchange concerns how to interpret and combine trials; it did not publish a corrected overall pain estimate.

Professional guidelines reach different recommendations

The 2019 American College of Rheumatology/Arthritis Foundation guideline^[12] strongly recommends against glucosamine for knee, hip and hand osteoarthritis, and against glucosamine–chondroitin combinations for knee and hip osteoarthritis. It emphasizes the lack of important benefit in the studies judged least likely to be biased.

The 2019 ESCEO European expert algorithm^[13] instead strongly recommends prescription crystalline glucosamine sulfate as long-term background treatment for knee osteoarthritis and discourages other glucosamine formulations. Its recommendation is specific to that preparation. The same algorithm gives a weak recommendation against glucosamine–chondroitin combinations as background treatment. ESCEO funded the working group; the paper also discloses corporate grants to the organization and individual authors' company relationships.

The 2021 American Academy of Orthopaedic Surgeons guideline^[14] takes a more tentative position: glucosamine may help pain and function in mild-to-moderate knee osteoarthritis, but the evidence is inconsistent and its recommendation has Limited strength.

The bottom line

Glucosamine remains an uncertain choice for knee osteoarthritis. Some crystalline-sulfate studies found modest symptom benefits and less joint-space narrowing; the large hydrochloride trial and the later LEGS pain comparison were less encouraging. Professional recommendations range from strongly against glucosamine to support for a specific prescription sulfate preparation.

The useful label distinctions are the salt, the full-serving amount and any added ingredients. If you take warfarin, speak with the prescriber before using glucosamine, with or without chondroitin.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.

Your name

Email address

What would you like to share?Select a topicCorrectionSource or research suggestionArticle requestAccessibility issueBusiness inquirySomething else

Your message

Continue to email →Email us directly